Integral Health Asset Management LLC Cuts Stock Position in Oric Pharmaceuticals, Inc. $ORIC

Integral Health Asset Management LLC lessened its holdings in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) by 28.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 900,000 shares of the company’s stock after selling 350,000 shares during the quarter. Integral Health Asset Management LLC owned about 0.93% of Oric Pharmaceuticals worth $10,800,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vivo Capital LLC boosted its stake in shares of Oric Pharmaceuticals by 50.3% in the 2nd quarter. Vivo Capital LLC now owns 3,126,604 shares of the company’s stock valued at $31,735,000 after buying an additional 1,046,154 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Oric Pharmaceuticals by 3,646.1% during the second quarter. JPMorgan Chase & Co. now owns 1,335,448 shares of the company’s stock worth $13,555,000 after buying an additional 1,299,799 shares during the period. Alkeon Capital Management LLC raised its holdings in shares of Oric Pharmaceuticals by 12.5% in the 2nd quarter. Alkeon Capital Management LLC now owns 4,504,096 shares of the company’s stock valued at $45,717,000 after purchasing an additional 500,000 shares in the last quarter. Resolute Capital Asset Partners LLC purchased a new stake in shares of Oric Pharmaceuticals during the 2nd quarter worth $2,309,000. Finally, Royce & Associates LP grew its stake in shares of Oric Pharmaceuticals by 521.2% during the third quarter. Royce & Associates LP now owns 1,458,483 shares of the company’s stock worth $17,502,000 after purchasing an additional 1,223,709 shares in the last quarter. Hedge funds and other institutional investors own 95.05% of the company’s stock.

Insider Activity

In other news, insider Pratik S. Multani sold 10,720 shares of the business’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $9.06, for a total transaction of $97,123.20. Following the transaction, the insider directly owned 68,149 shares in the company, valued at $617,429.94. The trade was a 13.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jacob Chacko sold 33,374 shares of the stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $9.06, for a total value of $302,368.44. Following the transaction, the chief executive officer directly owned 581,711 shares of the company’s stock, valued at approximately $5,270,301.66. This trade represents a 5.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 106,814 shares of company stock valued at $1,199,135 over the last quarter. Corporate insiders own 6.82% of the company’s stock.

Oric Pharmaceuticals Stock Up 1.2%

Shares of ORIC stock opened at $11.90 on Friday. Oric Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $14.93. The stock’s 50-day moving average price is $11.32 and its 200 day moving average price is $11.23. The stock has a market capitalization of $1.19 billion, a PE ratio of -7.83 and a beta of 1.28.

Oric Pharmaceuticals (NASDAQ:ORIC) last announced its earnings results on Monday, February 23rd. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.04. Analysts expect that Oric Pharmaceuticals, Inc. will post -2.17 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on ORIC shares. Cantor Fitzgerald restated an “overweight” rating on shares of Oric Pharmaceuticals in a research note on Monday. Wall Street Zen raised Oric Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. JPMorgan Chase & Co. increased their price objective on Oric Pharmaceuticals from $17.00 to $20.00 and gave the company an “overweight” rating in a report on Tuesday, November 18th. Evercore assumed coverage on Oric Pharmaceuticals in a research report on Thursday, November 20th. They set an “outperform” rating and a $25.00 target price on the stock. Finally, Wolfe Research assumed coverage on Oric Pharmaceuticals in a research note on Tuesday, November 18th. They set a “peer perform” rating for the company. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Oric Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.20.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.